Ignite Creation Date:
2024-05-06 @ 3:46 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04753112
Status:
COMPLETED
Last Update Posted:
2021-09-28
First Post:
2021-02-01
Brief Title:
Treatment of PH With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in HFpEF Patients With CardioMEMS Device
Sponsor:
Germans Trias i Pujol Hospital
Organization:
Germans Trias i Pujol Hospital
Study Overview
Official Title:
Treatment of Pulmonary Hypertension With Angiotensin II Receptor Blocker and Neprilysin Inhibitor in Patients With Heart Failure With Preserved Ejection Fraction Monitored With the CardioMEMS Device ARNIMEMS-HFpEF
Status:
COMPLETED
Status Verified Date:
2021-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ARNIMEMS-HFpEF
Brief Summary:
This study will assess the impact of sacubitrilvalsartan on elevated pulmonary artery PA pressures in patients with heart failure HF with preserved ejection fraction HFpEF measured using a previously implanted hemodynamic monitoring device CardioMEMS
Detailed Description:
Fluid overload leading to increased PA pressure is one of the primary causes of HF related hospitalizations in HFpEF Signs and symptoms of fluid overload are not sensitive enough to reflect early pathophysiologic changes that increase the risk of decompensation Elevations in PA pressure may increase several days or weeks before signs and symptoms manifest
The CardioMEMS device is a small wireless sensor that is permanently implanted in the PA via a catheter inserted through the femoral vein The sensor measures PA pressure and is paired with a portable electronic transmitter The system allows patients to wirelessly transmit pressure readings to a secure online database from which treating physicians can access the data and adjust medication in response to PA pressure changes
The CHAMPION trial was a single blind randomized clinical trial that showed a significant and large reduction in hospitalizations in patients with NYHA class III HF who were managed with a the CardioMEMS device
More recently real life clinical practice has confirmed the value of PA pressure-guided therapy for HF PA pressures were reduced lower rates of HF hospitalizations and all-cause hospitalization and low rates of adverse events across a broad range of patients with symptomatic HF and prior HF hospitalizations were reported
The angiotensin receptor-neprilysin inhibitor ARNI led to a reduced risk of hospitalization for HF or death from cardiovascular causes among patients with HF and reduced ejection fraction in the PARADIGM-HF trial However it did not result in a significantly lower rate of total hospitalizations for HF and death from cardiovascular causes among patients with HF and an ejection fraction of 45 or higher in the PARAGON-HF trial despite there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women
ARNI reduced pulmonary pressures and vascular remodeling in an animal model of pulmonary hypertension PH and may be appropriate for treatment of PH and right ventricle dysfunction Data are lacking on the hemodynamic effects of ARNI on pulmonary hypertension in patients with HFpEF
This study will assess the impact of sacubitrilvalsartan on PA pressures measured using an implanted PA monitoring device The device will be used according to approved indications
The CardioMEMS device is a small wireless sensor that is permanently implanted in the PA via a catheter inserted through the femoral vein The sensor measures PA pressure and is paired with a portable electronic transmitter The system allows patients to wirelessly transmit pressure readings to a secure online database from which treating physicians can access the data and adjust medication in response to PA pressure changes
The CHAMPION trial was a single blind randomized clinical trial that showed a significant and large reduction in hospitalizations in patients with NYHA class III HF who were managed with a the CardioMEMS device
More recently real life clinical practice has confirmed the value of PA pressure-guided therapy for HF PA pressures were reduced lower rates of HF hospitalizations and all-cause hospitalization and low rates of adverse events across a broad range of patients with symptomatic HF and prior HF hospitalizations were reported
The angiotensin receptor-neprilysin inhibitor ARNI led to a reduced risk of hospitalization for HF or death from cardiovascular causes among patients with HF and reduced ejection fraction in the PARADIGM-HF trial However it did not result in a significantly lower rate of total hospitalizations for HF and death from cardiovascular causes among patients with HF and an ejection fraction of 45 or higher in the PARAGON-HF trial despite there was suggestion of heterogeneity with possible benefit with sacubitril-valsartan in patients with lower ejection fraction and in women
ARNI reduced pulmonary pressures and vascular remodeling in an animal model of pulmonary hypertension PH and may be appropriate for treatment of PH and right ventricle dysfunction Data are lacking on the hemodynamic effects of ARNI on pulmonary hypertension in patients with HFpEF
This study will assess the impact of sacubitrilvalsartan on PA pressures measured using an implanted PA monitoring device The device will be used according to approved indications
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None